From: Cost utility of fractional exhaled nitric oxide monitoring for the management of children asthma
Model input | Base case value | Distribution | References |
---|---|---|---|
Transition probabilities | |||
W to S | 0.097 | β(SD: 0.029) | [9] |
W to A | 0.004 | β(SD: 0.002) | |
S to W | 0.817 | β(SD: 0.038) | |
S to A | 0.007 | β(SD: 0.003) | |
A to W | 0.271 | β(SD: 0.044) | |
A to S | 0.052 | β(SD: 0.046) | |
Utility | |||
Well-controlled | 0.99 | β(SD: 0.016) | [9] |
Sub-optimal control | 0.70 | β(SD: 0.072) | |
Asthma exacerbation | 0.31 | β(SD: 0.070) | |
FeNO-SC effectiveness | |||
Relative risk of reduction of exacerbations | 0.76 | LogN(SD: 0.274) |